Sangamo Therapeutics, Inc. reports impairment charges for the three months ended September 30, 2023. For the quarter, Impairment of long-lived assets was $44.8 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.592 USD | +2.42% | +2.18% | +6.76% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.76% | 120M | |
+17.67% | 125B | |
+14.34% | 108B | |
-7.38% | 23.64B | |
+2.47% | 22.39B | |
-12.32% | 17.78B | |
-41.74% | 16.43B | |
-15.90% | 16.34B | |
+0.31% | 13.56B | |
+24.44% | 11.59B |
- Stock Market
- Equities
- SGMO Stock
- News Sangamo Therapeutics, Inc.
- Sangamo Therapeutics, Inc. Reports Impairment Charges for the Three Months Ended September 30, 2023